CA2065346A1 - Tumor necrosis factor-.alpha. and-.beta. receptors - Google Patents

Tumor necrosis factor-.alpha. and-.beta. receptors

Info

Publication number
CA2065346A1
CA2065346A1 CA002065346A CA2065346A CA2065346A1 CA 2065346 A1 CA2065346 A1 CA 2065346A1 CA 002065346 A CA002065346 A CA 002065346A CA 2065346 A CA2065346 A CA 2065346A CA 2065346 A1 CA2065346 A1 CA 2065346A1
Authority
CA
Canada
Prior art keywords
necrosis factor
tumor necrosis
receptors
beta
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002065346A
Other languages
French (fr)
Other versions
CA2065346C (en
Inventor
Craig A. Smith
Raymond G. Goodwin
M. Patricia Beckmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunex Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA002485553A priority Critical patent/CA2485553A1/en
Publication of CA2065346A1 publication Critical patent/CA2065346A1/en
Application granted granted Critical
Publication of CA2065346C publication Critical patent/CA2065346C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Tumor necrosis factor receptor proteins, DNAs and expression vectors encoding TNF receptors, and processes for producing TNF receptors as products of recombinant cell culture, are disclosed.
CA002065346A 1989-09-05 1990-07-17 Tumor necrosis factor-.alpha. and-.beta. receptors Expired - Lifetime CA2065346C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002485553A CA2485553A1 (en) 1989-09-05 1990-07-17 Tumor necrosis factor - .alpha. and - .beta. receptors

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US40324189A 1989-09-05 1989-09-05
US403,241 1989-09-05
US40537089A 1989-09-11 1989-09-11
US405,370 1989-09-11
US42141789A 1989-10-13 1989-10-13
US421,417 1989-10-13
PCT/US1990/004001 WO1991003553A1 (en) 1989-09-05 1990-07-17 TUMOR NECROSIS FACTOR-α AND -β RECEPTORS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA002485553A Division CA2485553A1 (en) 1989-09-05 1990-07-17 Tumor necrosis factor - .alpha. and - .beta. receptors

Publications (2)

Publication Number Publication Date
CA2065346A1 true CA2065346A1 (en) 1991-03-06
CA2065346C CA2065346C (en) 2005-03-29

Family

ID=46201946

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002065346A Expired - Lifetime CA2065346C (en) 1989-09-05 1990-07-17 Tumor necrosis factor-.alpha. and-.beta. receptors
CA002485553A Expired - Lifetime CA2485553A1 (en) 1989-09-05 1990-07-17 Tumor necrosis factor - .alpha. and - .beta. receptors

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002485553A Expired - Lifetime CA2485553A1 (en) 1989-09-05 1990-07-17 Tumor necrosis factor - .alpha. and - .beta. receptors

Country Status (3)

Country Link
AU (1) AU630497B2 (en)
CA (2) CA2065346C (en)
WO (1) WO1991003553A1 (en)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221675B1 (en) 1989-04-21 2001-04-24 Amgen, Inc. TNF receptors, TNF binding proteins and DNAs coding for them
DE59010941D1 (en) 1989-04-21 2005-03-24 Amgen Inc TNF receptor, TNF-binding proteins and DNAs coding therefor
US7264944B1 (en) 1989-04-21 2007-09-04 Amgen Inc. TNF receptors, TNF binding proteins and DNAs coding for them
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc Method for the production of a human recombinant tumor necrosis factor inhibitor
US6143866A (en) * 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
ATE194384T1 (en) * 1989-09-12 2000-07-15 Hoffmann La Roche TNF-BINDING PROTEINS
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
DE69130262T2 (en) * 1991-03-29 1999-03-18 Immunex Corp., Seattle, Wash. ISOLATED VIRAL PROTEINS AS CYTOKINANTAGONISTS
WO1993006128A1 (en) * 1991-09-16 1993-04-01 Peptide Technology Limited Tnf antagonist peptides
CA2121473C (en) * 1991-10-15 2001-05-01 Michael Mullarkey Methods and compositions for treating allergic reactions
EP0620739A4 (en) * 1992-09-15 1997-01-15 Immunex Corp Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists.
AU696560B2 (en) * 1993-03-19 1998-09-10 Fred D. Finkelman Pharmaceutical compositions comprising a ligand complexed with a soluble receptor
NZ278607A (en) * 1994-02-07 1999-05-28 Knoll Ag Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above
JP4344404B2 (en) 1996-02-09 2009-10-14 アムジェン インコーポレイテッド Composition comprising interleukin-1 inhibitor and controlled release polymer
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
ES2207759T3 (en) 1996-12-06 2004-06-01 Amgen Inc. COMBINATION THERAPY USING A PROTEIN OF UNION OF THE TUMOR NECROSIS FACTOR (TNF) IN THE TREATMENT OF DISEASES Induced by TNF.
EP0949931B1 (en) 1996-12-06 2008-08-27 Amgen Inc., Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases
US6893838B1 (en) 1998-04-07 2005-05-17 Genetics Institute Llc DADD, death activator death domain protein
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US20080213778A1 (en) 1998-12-30 2008-09-04 Millennium Pharmaceuticals, Inc. Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
US7041474B2 (en) * 1998-12-30 2006-05-09 Millennium Pharmaceuticals, Inc. Nucleic acid encoding human tango 509
ES2241599T3 (en) * 1999-05-10 2005-11-01 Chugai Seiyaku Kabushiki Kaisha CELL CULTURE METHOD.
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
MXPA02011682A (en) 2000-05-26 2003-05-14 Immunex Corp Use of interleukin-4 antagonists and compositions thereof.
PT2270052T (en) 2001-06-26 2018-07-04 Amgen Fremont Inc OPGL ANTIBODIES
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
CA2800126A1 (en) 2002-07-19 2004-01-29 Abbott Biotechnology Ltd. Treatment of tnf.alpha. related disorders
TW201705980A (en) 2004-04-09 2017-02-16 艾伯維生物技術有限責任公司 Multiple-variable dose regimen for treating TNF[alpha]-related disorders
GB0414054D0 (en) 2004-06-23 2004-07-28 Owen Mumford Ltd Improvements relating to automatic injection devices
WO2006125229A2 (en) 2005-05-16 2006-11-23 Abbott Biotechnology Ltd. Use of tnf inhibitor for treatment of erosive polyarthritis
US20070041905A1 (en) 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
US7919264B2 (en) 2005-11-01 2011-04-05 Abbott Biotechnology Ltd. Methods and compositions for determining the efficacy of a treatment for ankylosing spondylitis using biomarkers
US8007790B2 (en) 2006-04-03 2011-08-30 Stowers Institute For Medical Research Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases
CA2564435A1 (en) 2006-04-10 2007-10-10 Abbott Biotechnology Ltd. Methods for monitoring and treating intestinal disorders
EP2666479A3 (en) 2006-04-10 2014-03-26 Abbott Biotechnology Ltd Uses and compositions for treatment of juvenile rheumatoid arthritis
WO2008063213A2 (en) 2006-04-10 2008-05-29 Abbott Biotechnology Ltd. Uses and compositions for treatment of psoriatic arthritis
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
CN107243099A (en) 2006-06-30 2017-10-13 艾伯维生物技术有限公司 Automated injection device
DK2061803T4 (en) 2006-08-28 2022-12-05 Ares Trading Sa PROCEDURE FOR PURIFICATION OF FC-CONTAINING PROTEINS
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
EP2679995A1 (en) 2007-05-31 2014-01-01 AbbVie Inc. Biomarkers predictive of the responsiveness to TNF-alfa inhibitors in autoimmune disorders
WO2008154543A2 (en) 2007-06-11 2008-12-18 Abbott Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis
AU2009333489A1 (en) 2008-12-30 2010-07-08 Centocor Ortho Biotech Inc. Serum markers predicting clinical response to anti-TNF antibodies in patients with ankylosing spondylitis
MX2011011541A (en) 2009-04-29 2012-02-28 Abbott Biotech Ltd Automatic injection device.
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
JP2013514388A (en) 2009-12-16 2013-04-25 フィリップ ボッシュ， Method of treatment of interstitial cystitis
MX349856B (en) 2010-01-15 2017-08-16 Kirin Amgen Inc Antibody formulation and therapeutic regimens.
US20120014956A1 (en) 2010-02-02 2012-01-19 Hartmut Kupper Methods and compositions for predicting responsiveness to treatment with tnf-alpha inhibitor
CN103118737B (en) 2010-04-21 2015-05-20 艾伯维生物技术有限公司 Wearable automatic injection device for controlled delivery of therapeutic agents
WO2011146727A1 (en) 2010-05-19 2011-11-24 Philip Bosch Methods of treating interstitial cystitis
ES2685607T3 (en) 2010-06-03 2018-10-10 Abbvie Biotechnology Ltd Uses and compositions for the treatment of Hidradenitis Suppurativa (HS)
EP2490024A1 (en) 2010-12-22 2012-08-22 Proteomika, S.L. Method to optimize the treatment of patients with biological drugs
CA2825316C (en) 2011-01-24 2020-05-05 Abbvie Biotechnology Ltd. Automatic injection devices having overmolded gripping surfaces
MX2013010699A (en) 2011-03-18 2014-03-27 Abbvie Inc Systems, devices and methods for assembling automatic injection devices and sub-assemblies thereof.
EP2691134B2 (en) 2011-03-29 2020-10-07 AbbVie Inc. Improved shroud deployment in automatic injection devices
CN103619378B (en) 2011-04-21 2017-03-01 艾伯维公司 wearable automatic injection device
US20140234330A1 (en) 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
EP2941243A4 (en) 2013-01-04 2016-09-14 Massachusetts Inst Technology SURFACE BONDING OF NANOPARTICLE MEDICAMENTS ADMINISTERED TO TISSUE
EP3126392B1 (en) 2014-03-31 2019-09-11 Kirin-Amgen, Inc. Methods of treating nail and scalp psoriasis
WO2016102328A1 (en) 2014-12-22 2016-06-30 Ares Trading S.A. Liquid pharmaceutical composition
EP3440113A1 (en) 2016-04-08 2019-02-13 Gilead Sciences, Inc. Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
AU2017370937A1 (en) 2016-12-07 2019-05-30 Biora Therapeutics, Inc. Gastrointestinal tract detection methods, devices and systems
US20190343425A1 (en) 2016-12-14 2019-11-14 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
JOP20190162A1 (en) 2016-12-30 2019-06-27 Biocad Joint Stock Co Aqueous Pharmaceutical Composition of a Recombinant Monoclonal Antibody to TNF?
WO2019246313A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
KR20210030947A (en) 2018-07-03 2021-03-18 노파르티스 아게 Methods of treatment or selection of therapeutic agents for TNF inhibitor-resistant subjects using NLRP3 antagonists
WO2020086728A1 (en) 2018-10-24 2020-04-30 Novartis Inflammasome Research, Inc. Compounds and compositions for treating conditions associated with nlrp activity
JP2022506891A (en) 2018-11-13 2022-01-17 ノバルティス アーゲー Compounds and compositions for treating conditions associated with NLRP activity
CN113166081A (en) 2018-11-13 2021-07-23 诺华股份有限公司 Compounds and compositions for treating conditions associated with NLRP activity
US20220249814A1 (en) 2018-11-19 2022-08-11 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
EP3914583A1 (en) 2019-01-22 2021-12-01 Novartis AG Compounds and compositions for treating conditions associated with nlrp activity
WO2021002887A1 (en) 2019-07-02 2021-01-07 Novartis Inflammasome Research, Inc. Gut-targeted nlrp3 antagonists and their use in therapy
CN115666704B (en) 2019-12-13 2025-09-26 比特比德科有限责任公司 Ingestible device for delivering therapeutic agents to the gastrointestinal tract
TW202421172A (en) 2022-09-07 2024-06-01 美商Ｍｄｘ管理有限責任公司 Shp-1 inhibitors for treating cancer
EP4611752A1 (en) 2022-11-02 2025-09-10 MDX Management LLC Combination of a tyrosine kinase inhibitor and a pro-inflammatory agent for treating cancer
TW202444339A (en) 2023-03-17 2024-11-16 美商Ｍｄｘ管理有限責任公司 Compositions and methods for ameliorating adverse effects of therapies
WO2025038745A1 (en) 2023-08-16 2025-02-20 Mdx Management Llc Compositions and methods for activating immune cells
TW202525846A (en) 2023-08-25 2025-07-01 美商普羅特歐拉吉克適美國公司 Anti-il-13 multispecific antibody constructs and uses thereof
WO2025188914A1 (en) 2024-03-06 2025-09-12 Mdx Management Llc Tyrosine phosphatase inhibitor 1 (tpi-1) derivatives

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL83878A (en) * 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
GB8806339D0 (en) * 1988-03-17 1988-04-13 Hoffmann La Roche Monoclonal antibodies
GB8807803D0 (en) * 1988-03-31 1988-05-05 Glaxo Group Ltd Biochemical product

Also Published As

Publication number Publication date
CA2485553A1 (en) 1991-03-21
CA2065346C (en) 2005-03-29
WO1991003553A1 (en) 1991-03-21
AU6178190A (en) 1991-04-08
AU630497B2 (en) 1992-10-29

Similar Documents

Publication Publication Date Title
CA2065346A1 (en) Tumor necrosis factor-.alpha. and-.beta. receptors
GR3019333T3 (en) Tumor necrosis factor-alpha and -beta receptors
EP0318296A3 (en) Interleukin-1 receptors
CA2125763C (en) P40 homodimer of interleukin-12
IL98205A0 (en) Type ii interleukin-1 receptors
CA2032191A1 (en) Expression of the recombinant tumor necrosis factor binding protein i (tbp-i)
CA2267670A1 (en) Method for preparing human stem cell factor polypeptide
KR19980701570A (en)
AU9482498A (en) Interleukin-17 receptor-like protein
IL91705A0 (en) Interleukin-4 receptors,dna and expression vectors encoding them and process for producing the receptors
PT85349A (en) Method for the preparation of proteins with factor viii activity by microbial host cells expression vectors host cells antibodies
ATE365796T1 (en) TUMOR NECROSIS FACTOR RECEPTORS 6 ALPHA & 6 BETA
CA2108473A1 (en) Heregulins (hrgs) binding proteins of p185erb2
EP0103395A3 (en) Dna sequences, recombinant dna molecules and processes for producing bovine growth hormone-like polypeptides in high yield
CA2285040A1 (en) Death domain containing receptor 5
NZ218332A (en) Il-4(interleukin-4), recombinant production, dna, vectors and pharmaceutical composition
IE902158L (en) Interleukin-7 Receptors
IL88151A0 (en) Interleukin-7,its preparation and compositions containing it
IL87622A0 (en) Recombinant eukaryotic cells producing interleukin-2,process and vectors for their preparation and process for the preparation of interleukin-2
GB2171703B (en) Expression-secretion vector for gene expression and protein secretion, recombinant dna including the vector, and method of producing proteins by use of the re
EP0170266A3 (en) Process for producing protein, and vector, recombinant dna and transformant used therefor
CA2051010A1 (en) Human luteinizing hormone-chorionic gonadotropin receptor protein, dna and use thereof
DK0494260T3 (en) Receptors for granulocyte colony stimulating factor
ZA875267B (en) Method for the preparation of proteins with factor viii activity by microbial host cells;expression vectors,host cells,antibodies
NZ536317A (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry